46-60 of 173

Beyond RAASi and Approved Therapies: The Unmet Needs in IgAN
MinuteCE®Beyond RAASi and Approved Therapies: The Unmet Needs in IgAN

Emerging Evidence: IgAN Disease-Modifying Agents
MinuteCE®Emerging Evidence: IgAN Disease-Modifying Agents

Emerging Therapies in IgAN: Who Could Benefit the Most?
MinuteCE®Emerging Therapies in IgAN: Who Could Benefit the Most?

Targeting Lower Proteinuria Levels: Shifting the Goalpost in IgAN
MinuteCE®Targeting Lower Proteinuria Levels: Shifting the Goalpost in IgAN

Translating Guidelines to Action in IgAN: Embracing a Simultaneous Dual-Concordant Approach
MinuteCE®Translating Guidelines to Action in IgAN: Embracing a Simultaneous Dual-Concordant Approach
- advertisement

Inside the IgAN Clinic: Shared Decision-Making Into Practice
CME/CEInside the IgAN Clinic: Shared Decision-Making Into Practice

Targeting CKD-aP at the Source: Key Mechanisms and Treatments
CME/CETargeting CKD-aP at the Source: Key Mechanisms and Treatments

Case-Based Approach: Managing Hyperkalemia in Patients With CKD and Heart Failure
CME/CECase-Based Approach: Managing Hyperkalemia in Patients With CKD and Heart Failure

No Patient with CKD Left Behind! Emerging CKD Therapies in T1D
CME/CENo Patient with CKD Left Behind! Emerging CKD Therapies in T1D

A New Paradigm in IgAN Management—Advancing Clinical Practice in the Era of Therapeutic Expansion
CME/CEA New Paradigm in IgAN Management—Advancing Clinical Practice in the Era of Therapeutic Expansion

Nephrology at the Helm—Advancing Timely CKD Care Through Cross-Specialty Collaboration
CME/CENephrology at the Helm—Advancing Timely CKD Care Through Cross-Specialty Collaboration
- advertisement

Quantification du Pa-MRC : des outils pour améliorer les soins
MinuteCE®Quantification du Pa-MRC : des outils pour améliorer les soins






















































